Daniel Getts, MBA, PhD

CREATE Medicines is a clinical stage biotech company pioneering in vivo CAR therapies with an mRNA-LNP platform that programs immune cells directly inside the body and enables scalable, repeat dose, off-the-shelf treatments.
CREATE has the largest clinical data set in the in vivo CAR field with more than 40 patients treated, showing tolerable repeat dosing, clear proof of mechanism, and immune remodeling across several tumor types, which reduces development risk across the portfolio.
- The company recently reported the first clinical success of an in vivo CAR therapy outside of blood cancers, achieving a partial response lasting 16 months in an HR+ breast cancer patient treated with MT-302.
The company’s mRNA-LNP platform supports a broad therapeutic footprint across oncology, autoimmune disease, and fibrosis, including oncology programs spanning frontline myeloid CAR therapies and multi-immune CAR designs that engage T cells, NK cells, and myeloid cells to drive deeper and more durable responses.
CREATE has developed RetroT, an all-RNA gene delivery technology capable of transient or durable CAR expression without viral vectors or DNA templates, providing important flexibility for next generation immunotherapies across autoimmunity and oncology.

CREATE Medicines, Inc.